Back to regulatory watch
Federal RegisterGuidance and regulationPublished Sep 15, 2026

Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of HPV 16 E6-Expressing Cancers

Updated 2 hours ago ()

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to MedGene Therapeutics, Inc. ("MedGene"), a company located in Silver Spring, Maryland, the United States of America.

Tags
health IT, Notice, Health and Human Services Department, National Institutes of Health
Related exam domains
None matched
Source record id
2026-18877
First seen by InfoSec Signals
Sep 23, 2026

Source: Federal Register API, Office of the Federal Register, National Archives and Records Administration about this source more from it

Exam domain labels come from a keyword heuristic and are study hints, not an official mapping. The summary is the publisher's own text, shortened; the linked record is authoritative.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.